摘要
目的:探讨血清肿瘤标志物神经元特异性烯醇化酶(NSE)对肺癌的诊断、评估化疗敏感性及病情监测的临床价值。方法:采用酶联免疫分析方法检测96例肺癌患者、60例肺部良性疾病患者和60例健康对照组血清NSE水平。结果:肺癌患者血清NSE水平显著高于肺部良性疾病患者及健康人(P<0.001),其中小细胞肺癌(SCLC)患者NSE水平显著高于肺腺癌及肺鳞癌(P<0.001)。SCLC中扩展性病变血清NSE水平明显高于局限性病变,而非小细胞肺癌(NSCLC)组血清NSE水平同NSCLC临床分期无关联性(P>0.05)。NSCLC组和SCLC组NSE阳性者肺癌近期化疗有效率(66.67%和87.10%)高于NSE阴性者(33.33%和40.00%)(P<0.05)。结论:血清NSE是一种有效的肺癌肿瘤标志物。
Objective To study the clinical values of neuron-specific enolase （NSE） as serum tumor marker in lung cancer. Methods The serum NSE levels in 96 patients with lung cancer, 60 patients with begnign pulmonary disease and 60 healthy controls were measured by using enzyme-linked immunosorbent assay. Results The levels of NSE in serum in patients with lung cancer was significantly higher than those in healthy subjects and patients with begnign lung disease （P〈0. 001）, the level and positive rate of NSE in patients with small cell lung cancer （SCLC） were higher than those of patients with adenoearcinoma or squamous cell carcinoma （P〈0. 001）. An elevated NSE level was found more frequently in patients with extensive disease of SCLC than those in patients with limited disease, but no significant positive correlation was found between serum NSE level and TNM staging in non-small cell lung cancer patients （P〉0. 05）. The effective rate of chemotherapy were 87. 10%, 40.00% and 66.67%, 33.33% in patients with SCLC and NSCLC, respective for NSE positive and negative ones （P 〈 0.05）. Conclusion NSE can be used as a useful tumor marker in patients with lung cancer.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2006年第4期687-689,共3页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅科技发展计划项目资助课题(963003-3)
